Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, ... Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -12.582781457 | 1.51 | 2.03 | 1.32 | 870351 | 1.85250232 | CS |
4 | -0.21 | -13.7254901961 | 1.53 | 2.08 | 1.32 | 810095 | 1.75349633 | CS |
12 | -0.19 | -12.582781457 | 1.51 | 2.64 | 1.14 | 2130871 | 1.87196316 | CS |
26 | -5.755 | -81.3427561837 | 7.075 | 7.25 | 1.14 | 2183339 | 2.66856505 | CS |
52 | -8.805 | -86.962962963 | 10.125 | 17.1125 | 1.14 | 1263164 | 3.49849912 | CS |
156 | -18.68 | -93.4 | 20 | 31.5 | 1.14 | 664856 | 6.35932502 | CS |
260 | -18.68 | -93.4 | 20 | 31.5 | 1.14 | 664856 | 6.35932502 | CS |
Symbole | Prix | Vol. |
---|---|---|
EONREON Resources Inc | US$ 1,33 (30,39%) | 133,23M |
MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 12,685 (-3,39%) | 66,54M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 33,69 (3,69%) | 60M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,79 (-2,53%) | 52,3M |
TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,13 (1,43%) | 48,56M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales